Glaxo pandemic flu vaccine works better than rivals’
Glaxo said its H5N1 vaccine uses a new additive, or adjuvant, to get a strong immune response at a low dose. The adjuvant augments the vaccine's potency, allowing a smaller dose of the immunization to be given and increasing the amount of people who can be inoculated in the event of a pandemic. Glaxo is also testing a shot with a standard aluminum-based additive. Adjuvants, from the Latin word „to help,” are substances used to enhance the ability of an antigen to stimulate the immune system.
At least 133 of the 231 people known to be infected with H5N1 have died, according to the World Health Organization in Geneva. A new death toll was reported this morning from Taiwan, where a young boy died of the infection. (Bloomberg)
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.